Please assess the completion status of the following clinical trial:

Trial Title: Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Estimated fetal weight \<10th percentile in combination with abnormal fetoplacental Doppler studies.~* Singleton pregnancy.~* Live fetus.~* Gestational age: from 23+0 weeks until 34+0 weeks.~* Normal fetal anatomy on ultrasound.~* Confirmed gestational age.~* No indication for immediate delivery.~* Basic understanding of the English language.~* 18 years or older.~* Consent obtained.~Exclusion Criteria:~* Fetal demise.~* Multiple pregnancy.~* Known abnormal karyotype.~* Presence of any congenital abnormality.~* Unknown duration of pregnancy.~* IUGR attributable to non-placental factors.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: EXPERIMENTAL): Women with IUGR will take 4mg prolonged release melatonin oral tablets twice daily. Treatment will occur as soon as the diagnosis of intrauterine growth restriction is made and the patient has been enrolled to this study until birth. The overall duration of treatment will vary due to the nature of intrauterine growth restriction.

Based on this trial design, predict the completion outcome and termination type (if applicable).